OmniSeq Immune Report Card® Assay

OmniSeq Immune Report Card® Assay

The OmniSeq Immune Report Card assay supports immunotherapy treatment decision making by providing comprehensive immune profiling from a single sample.   The assay measures multiple biomarkers present in DNA, RNA, proteins, and cells to comprehensively interrogate the cancer-immunity cycle.  A summary report is created personalized for a patient's immune profile and potential immunotherapy treatment options.


The Immune Report Card Assay uses five different testing methodologies (IHC, FISH, MSI, mutational burden, NGS sequencing) with the results consolidated into one summary report.


88360-TC, 88360-26, 81301, 88342, 88377, 81455 (81479 for Medicare), 88381


Bladder Cancer

Breast Cancer

Colorectal Cancer

Different cancer types

Gastroesophageal cancer

Lung Cancer


Non-Small-Cell Lung Cancer (NSCLC)

Ovarian Cancer

Prostate Cancer


FFPE tissue block preferred.  Unstained slides accepted.  


Block is preferred, or send 15 unbaked, positively charged, unstained slides cut at 5 µm.
If submitting a sample for both the OmniSeq Immune Report Card and OmniSeq Comprehensive Assay, submit 20 unbaked, positively charged, unstained slides cut at 5 µm.

Special Instructions

Primary tumor type and stage of disease required and needs to be included on the test requisition.  Please include the pathology report when submitting a sample.  If a pathology report is not received with the sample, testing will be delayed.

Causes for Rejection

Tumor block containing insufficient tumor; broken or stained slides; decalicified bone biopsies; cytology smears.  Specimens with very small amounts of tumor and/or less than requested number of slides will be accepted with the caveat that complete testing may not be possible.

Storage Instructions

FFPE blocks are stored at room temperature and shipped with no special precautions, except when daily outside temperatures exceed 35°C, and then ship with cool packs to avoid paraffin meltdown.

Test Includes

The Immune Report Card assay includes PD-L1( FDA-approved), microsatellite instability (MSI), tumor mutational burden, and gene expression of 54 specific immune markers related to tumor infiltrating lymphocytes and T-cell receptor signaling. 

Use Statement

The Immune Report Card assay measures multiple immune biomarkers present in DNA, RNA, proteins, and cells to comprehensively interrogate the cancer-immunity cycle.  Single biomarker assays only evaluate one or two steps in the immune cycle and thus may miss the complete picture.

CPT Codes

The CPT codes included in this publication are in accordance with Current Procedural Terminology, a publication of the American Medical Association. CPT codes are provided here for the convenience of our clients; however, correct coding often varies from one carrier to another, and LabCorp may bill specific carriers using codes other than those shown. Clients who bill for services should verify the code(s) with the applicable payor to confirm that their use is appropriate in each case.

Profile Policy

LabCorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/profiles does not prevent physicians who wish to order a test combination/profile from making deliberate informed decisions regarding which tests are medically necessary. All the tests offered in test combinations/profiles may be ordered individually using the LabCorp test request form.

Please remember that (1) when ordering tests for which Medicare or Medicaid reimbursement is sought, the physician should only order those tests that the physician believes are medically necessary for each patient, (2) that using a customized profile may result in ordering tests for which Medicare or Medicaid will deny payment, (3) that the physician should only order individual tests or a less inclusive profile where not all the tests in the customized test combination/profile are medically necessary for an individual patient, and (4) that the United States Department of Health and Human Services, Office of Inspector General, takes the position that a physician who orders medically unnecessary tests may be subject to civil penalties.

LabCorp encourages clients to contact their local LabCorp representative or LabCorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

Investigational Procedures

Some of the individual tests and profile test components listed in this Directory may be considered by Medicare or other insurance carriers as investigational procedures, and therefore, the test may not be payable by the carrier as a covered benefit for the patient. Medicare patients must be informed of this possibility when the physician orders tests that may fall into this category. Affected patients must be asked to sign an Advance Beneficiary Notice, agreeing to be financially responsible if the service is denied by the carrier. Additionally, for other insurance plans, physicians should inform the patient that the service(s) may not be covered by their private insurance plan and, if so, they will be financially responsible for payment. If the patient declines to accept financial responsibility, please do not order the test(s).

As with all clinical assays, results of these tests should be used only in conjunction with other medically established diagnostic elements (eg, symptoms, history, clinical impressions, results from other tests, etc). Physicians should use all the information available to them to diagnose and determine appropriate treatment for their patients. In order to obtain a current list of the procedures that may be considered investigational by Medicare or other insurance carriers, please contact your local LabCorp representative.